Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2011

01-07-2011 | Article

Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4

Authors: M. N. Pham, M. I. Hawa, C. Pfleger, M. Roden, G. Schernthaner, P. Pozzilli, R. Buzzetti, W. Scherbaum, J. Seissler, H. Kolb, S. Hunter, R. D. G. Leslie, N. C. Schloot, Action LADA Study Group

Published in: Diabetologia | Issue 7/2011

Login to get access

Abstract

Aims/hypothesis

Systemic pro- and anti-inflammatory cytokines are associated with both type 1 and type 2 diabetes, while their role in latent autoimmune diabetes in adults (LADA) is unclear. Therefore, we compared cytokine concentrations in patients with LADA, type 1 or type 2 diabetes and healthy individuals to test the hypothesis that differences of cytokine concentrations between all groups are attributable to diabetes type and BMI.

Methods

The pro-inflammatory cytokines IL-6 and TNF-α, and the anti-inflammatory cytokines IL-1 receptor antagonist (IL-1RA) and IL-10 were measured in 90 participants with type 1 diabetes, 61 with LADA, 465 with type 2 diabetes and 41 control participants using multiple regression models adjusted for BMI, sex, age, blood pressure and diabetes duration.

Results

Patients with type 2 diabetes had higher concentrations of systemic IL-1RA, IL-6 and TNF-α cytokines than patients with either LADA or type 1 diabetes (p < 0.0001 for all differences). Cytokine concentrations in controls were lower than those in all diabetes types (p < 0.04). Increased BMI was positively associated with higher systemic cytokine concentrations in all diabetes types (p < 0.0001). Despite the association of cytokines with anthropometric data, differences between diabetes forms persisted also after adjusting analysis for the confounders BMI, age, sex, disease duration and blood pressure (p < 0.04).

Conclusions/interpretation

Although body mass associates positively with pro- and anti-inflammatory cytokine levels, patients with type 2 diabetes have higher cytokine levels independent of the prevailing BMI. LADA and type 1 diabetes could not be distinguished by systemic cytokines.
Literature
1.
Butler AE, Janson J, Bonner-Weir, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110PubMedCrossRef
2.
3.
Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1973–1801
4.
Pickup JC, Crook MA (1998) Is type 2 diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241–1248PubMedCrossRef
5.
Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the immune system: association of acute phase reactants and interleukin-6 with metabolic syndrome. Diabetologia 40:1286–1292PubMedCrossRef
6.
7.
Herder C, Brunner EJ, Rathmann W et al (2009) Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 32:421–423PubMedCrossRef
8.
Carstensen M, Herder C, Kivimäki M et al (2010) Accelerated increase in serum interleukin-1 receptor antagonist (IL-1Ra) starts 6 years before diagnosis of type 2 diabetes: whitehall II prospective cohort study. Diabetes 59:1222–1227PubMedCrossRef
9.
Herder C, Zierer A, Koenig W, Roden M, Meisinger C, Thorand B (2009) Transforming growth factor-beta 1 and incident type 2 diabetes: results from the MONICA/KORA case cohort study, 1984–2002. Diabetes Care 32:1921–1923PubMedCrossRef
10.
He L, He M, Lv X, Pu D, Su P, Liu Z (2010) NF-kappaB binding activity and pro-inflammatory cytokines expression correlate with body mass index but not glycosylated haemoglobin in Chinese population. Diab Res Clin Pract 90:73–80CrossRef
11.
Ventre J, Doebber T, Wu M et al (1997) Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes 46:1526–1531PubMedCrossRef
12.
Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409–2415PubMedCrossRef
13.
Ziccardi P, Nappo F, Giugliano G et al (2002) Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105:804–809PubMedCrossRef
14.
Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 relation to adiposity, insulin action, and insulin secretion. Obes Res 97:414–417CrossRef
15.
Juge-Aubry CE, Somm E, Pernin A et al (2005) Adipose tissue is a regulated source of interleukin-10. Cytokine 29:270–274PubMed
16.
Juge-Aubry CE, Somm E, Giusti V et al (2003) Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 52:1104–1110PubMedCrossRef
17.
Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526PubMedCrossRef
18.
Atkinson MA, Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221–229PubMedCrossRef
19.
20.
Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL (2005) Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54(suppl2):S97–S107PubMedCrossRef
21.
Eizirik DL, Colli ML, Ortis F (2009) The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 5:219–226PubMedCrossRef
22.
Mandrup-Poulsen T (1990) Cytokine and free radicals as effector molecules in the destruction of pancreatic beta cells. Curr Top Microbiol Immunol 164:169–193PubMed
23.
Campbell IL, Oxbrow L, Harrison LC (1991) Reduction in Insulitis following administration of IFN-gamma and TNF-alpha in the NOD mouse. J Autoimm 4:249–262CrossRef
24.
Nicoletti F, Zaccone P, Di Marco R et al (1998) Paradoxical antidiabetogenic effect of gamma-interferon in DP-BB rats. Diabetes 47:32–38PubMedCrossRef
25.
Ortis F, Naamane N, Flamez D et al (2010) Cytokines interleukin-1β and tumor necrosis factor-α regulate different transcriptional and alternative splicing networks in primary β-cells. Diabetes 59:358–374PubMedCrossRef
26.
Hoorens A, Stangé G, Pavlovic D, Pipeleers D (2001) Distinction between interleukin-1-induced necrosis and apoptosis of islet cells. Diabetes 50:551–557PubMedCrossRef
27.
Pfleger C, Meierhoff G, Kolb H, Schloot NC, p520/521 Study Group (2010) Association of T cell reactivity with beta-cell function in recent onset type 1 diabetes patients. J Autoimmun 34:127–135PubMedCrossRef
28.
Pfleger C, Kaas A, Hansen L et al (2008) Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin Immunol 128:57–65PubMedCrossRef
29.
Pfleger C, Mortensen HB, Hansen L et al (2008) Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 57:929–937PubMedCrossRef
30.
Leslie RD, Kolb H, Schloot NC et al (2008) Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diab Metab Res Rev 24:511–519CrossRef
31.
Hosszúfalusi N, Vatay A, Rajczy K et al (2003) Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26:452–457PubMedCrossRef
32.
Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G (1993) Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis in type 2 diabetic patients. Diabetes Care 16:902–910PubMedCrossRef
33.
Hawa MI, Thivolet C, Mauricio D et al (2009) Metabolic syndrome and autoimmune diabetes: Action LADA 3. Diabetes Care 32:160–164PubMedCrossRef
34.
Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM (2002) IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin. J Clin Endocrinol Metab 87:1184–1188PubMedCrossRef
35.
Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T (1998) Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907–2910PubMedCrossRef
36.
Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132:2169–2180PubMedCrossRef
37.
Shoelson SE, Goldfine AB (2009) Getting away from glucose: fanning the flames of obesity-induced inflammation. Nat Med 15:373–374PubMedCrossRef
38.
Rolandsson O, Palmer JP (2010) Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes. Diabetologia 53:1250–1253PubMedCrossRef
39.
Pradhan AD, Manson JAE, Rifai N, Buring JE, Ridker (2001) C-reactive Protein, Interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMedCrossRef
40.
Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I (2006) Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55:774–779PubMedCrossRef
41.
Basu S, Larsson A, Vessby J, Vessby B, Berne C (2005) Type 1 diabetes is associated with increased cyclooxygenase and cytokine-mediated inflammation. Diab Care 28:1371–1375CrossRef
42.
Trøseid M, Seljeflot I, Hjerkinn EM, Arnesen H (2009) Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care 32:486–492PubMedCrossRef
43.
Hartkamp A, Geenen R, Bijl M, Kruize AA, Godaert GL, Derksen RH (2004) Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjogren’s syndrome. Ann Rheum Dis 63:1335–1337PubMedCrossRef
44.
Mysliwiec M, Zorena K, Balcerska A, Mysliwska J, Lipowski P, Raczynska K (2006) The activity of N-acetyl-beta-D-glucosaminidase and tumour necrosis factor-alpha at early stage of diabetic retinopathy development in type 1 diabetes mellitus children. Clin Biochem 39:851–856PubMedCrossRef
45.
Weihrauch MR, Manzke O, Beyer M et al (2005) Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin’s disease potential for a prognostic factor. Cancer Res 65:5516–5519PubMedCrossRef
Metadata
Title
Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4
Authors
M. N. Pham
M. I. Hawa
C. Pfleger
M. Roden
G. Schernthaner
P. Pozzilli
R. Buzzetti
W. Scherbaum
J. Seissler
H. Kolb
S. Hunter
R. D. G. Leslie
N. C. Schloot
Action LADA Study Group
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2088-6

Other articles of this Issue 7/2011

Diabetologia 7/2011 Go to the issue

Review

Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance

Article

Pancreatic alpha cell mass in European subjects with type 2 diabetes

Article

Synaptotagmin-7 as a positive regulator of glucose-induced glucagon-like peptide-1 secretion in mice

Article

Variants of ADRA2A are associated with fasting glucose, blood pressure, body mass index and type 2 diabetes risk: meta-analysis of four prospective studies

Short Communication

Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects

Article

RETRACTED ARTICLE: MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose- and AGE-mediated vascular cell damage
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits